VanEck Biotech ETF (NASDAQ:BBH) Major Shareholder Sells $20,260.03 in Stock

VanEck Biotech ETF (NASDAQ:BBH) major shareholder Sardar Biglari sold 1,211 shares of the firm’s stock in a transaction on Tuesday, July 14th. The shares were sold at an average price of $16.73, for a total value of $20,260.03. Following the sale, the insider directly owned 3,559,243 shares of the company’s stock, valued at $59,546,135.39. This represents a 0.03% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Major shareholders that own at least 10% of a company’s stock are required to disclose their transactions with the SEC.

Sardar Biglari also recently made the following trade(s):

• On Thursday, July 16th, Sardar Biglari sold 2,749 shares of VanEck Biotech ETF stock. The stock was sold at an average price of $16.70, for a total transaction of $45,908.30.
• On Wednesday, July 15th, Sardar Biglari sold 6,533 shares of VanEck Biotech ETF stock. The shares were sold at an average price of $16.71, for a total transaction of $109,166.43.

VanEck Biotech ETF Trading Down 1.0%

NASDAQ:BBH opened at $204.23 on Friday. The firm’s fifty day moving average price is $193.07 and its two-hundred day moving average price is $191.95. VanEck Biotech ETF has a one year low of $154.75 and a one year high of $212.54.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Jane Street Group LLC bought a new position in VanEck Biotech ETF in the 1st quarter valued at about $659,000. Raymond James Financial Inc. lifted its position in VanEck Biotech ETF by 245.9% during the second quarter. Raymond James Financial Inc. now owns 67,940 shares of the company’s stock worth $10,414,000 after acquiring an additional 48,297 shares during the last quarter. Bank of America Corp DE boosted its holdings in shares of VanEck Biotech ETF by 17.7% during the second quarter. Bank of America Corp DE now owns 52,466 shares of the company’s stock worth $8,042,000 after acquiring an additional 7,898 shares during the period. Corient Private Wealth LLC boosted its holdings in shares of VanEck Biotech ETF by 63.5% during the second quarter. Corient Private Wealth LLC now owns 13,290 shares of the company’s stock worth $2,037,000 after acquiring an additional 5,160 shares during the period. Finally, Osaic Holdings Inc. grew its position in shares of VanEck Biotech ETF by 87.1% in the second quarter. Osaic Holdings Inc. now owns 1,465 shares of the company’s stock valued at $225,000 after purchasing an additional 682 shares during the last quarter. Institutional investors and hedge funds own 32.05% of the company’s stock.

About VanEck Biotech ETF

The BIOTECH HOLDING COMPANY DEPOSITARY RECEIPTS or HOLDRS TRUST was formed under the depositary trust agreement, among The Bank of New York, as trustee, Merrill Lynch, Pierce, Fenner & Smith Incorporated, other depositors and the owners of the Biotech HOLDRS. The trust currently holds shares of common stock or American depositary shares issued by a group of companies that were, at the time of the initial offering, generally considered to be involved in various segments of thebiotechnology industry.